Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review

Anita Archwamety; Ruchira Ruangchira-Urai; Charuwan Akewanlop; Krittiya Korphaisarn

doi:10.1111/1759-7714.14580

Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review

Thorac Cancer. 2022 Sep;13(17):2539-2541. doi: 10.1111/1759-7714.14580. Epub 2022 Jul 13.

Authors

Anita Archwamety¹, Ruchira Ruangchira-Urai², Charuwan Akewanlop¹, Krittiya Korphaisarn¹

Affiliations

¹ Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
² Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Abstract

Here, we report a case of metastatic Epstein-Barr virus (EBV)-related primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) in a young, nonsmoking female who responded well to treatment with two types of immune checkpoint inhibitors (ICIs). This is the first case report of a favorable outcome to ICIs in the late-line treatment of advanced PPLELC patients with programmed cell death-ligand 1 (PD-L1) expression.

Keywords: PPLELC; immune checkpoint inhibitor; primary pulmonary lymphoepithelioma-like carcinoma.

Publication types

Case Reports
Review

MeSH terms

B7-H1 Antigen / metabolism
Carcinoma, Squamous Cell*
Epstein-Barr Virus Infections* / complications
Female
Herpesvirus 4, Human / metabolism
Humans
Immunotherapy

Substances

B7-H1 Antigen